[S02DA03, antipyrine, The risk or severity of gastrointestinal bleeding can be increased when Antipyrine is combined with Zoledronic acid.]
[J01GA01, streptomycin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Streptomycin is combined with Zoledronic acid.]
[M01AB02, sulindac, The risk or severity of gastrointestinal bleeding can be increased when Sulindac is combined with Zoledronic acid.]
[M01AX04, apazone, The risk or severity of gastrointestinal bleeding can be increased when Azapropazone is combined with Zoledronic acid.]
[J01DI02, ceftaroline fosamil, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftaroline fosamil is combined with Zoledronic acid.]
[L04AX02, thalidomide, The risk or severity of jaw osteonecrosis can be increased when Thalidomide is combined with Zoledronic acid.]
[B03AB03, sodium ironedetate, Sodium feredetate can cause a decrease in the absorption of Zoledronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01AA12, tobramycin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tobramycin is combined with Zoledronic acid.]
[M02AA21, tolmetin, The risk or severity of gastrointestinal bleeding can be increased when Tolmetin is combined with Zoledronic acid.]
[C03DB02, triamterene, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Triamterene is combined with Zoledronic acid.]
[S01AA28, vancomycin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Vancomycin is combined with Zoledronic acid.]
[M05BA05, tiludronic acid, The risk or severity of adverse effects can be increased when Zoledronic acid is combined with Tiludronic acid.]
[M05BA06, ibandronic acid, The risk or severity of adverse effects can be increased when Zoledronic acid is combined with Ibandronate.]
[N02BA01, aspirin, The risk or severity of gastrointestinal bleeding can be increased when Acetylsalicylic acid is combined with Zoledronic acid.]
[S01LA05, aflibercept, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Aflibercept is combined with Zoledronic acid.]
[R02AB04, bacitracin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Bacitracin is combined with Zoledronic acid.]
[A02AA05, magnesium silicate, The serum concentration of Zoledronic acid can be decreased when it is combined with Magnesium silicate.]
[A02AC02, calcium silicate, The serum concentration of Zoledronic acid can be decreased when it is combined with Calcium silicate.]
[L04AX06, pomalidomide, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Pomalidomide is combined with Zoledronic acid.]
[N02BA10, benorilate, The risk or severity of gastrointestinal bleeding can be increased when Benorilate is combined with Zoledronic acid.]
[M01AH01, celecoxib, The risk or severity of gastrointestinal bleeding can be increased when Celecoxib is combined with Zoledronic acid.]
[R02AX03, benzydamine, The risk or severity of gastrointestinal bleeding can be increased when Benzydamine is combined with Zoledronic acid.]
[H05AA03, parathyroid hormone, The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Zoledronic acid.]
[B03AB04, ferric hydroxide, Ferric hydroxide can cause a decrease in the absorption of Zoledronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V03AE05, sucroferric oxyhydroxide, Iron sucrose can cause a decrease in the absorption of Zoledronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J05AF08, adefovir dipivoxil, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Adefovir dipivoxil is combined with Zoledronic acid.]
[M05BA01, etidronic acid, The risk or severity of adverse effects can be increased when Zoledronic acid is combined with Etidronic acid.]
[M05BA03, pamidronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Pamidronic acid is combined with Zoledronic acid.]
[S01AA15, dihydrostreptomycin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Dihydrostreptomycin is combined with Zoledronic acid.]
[V03AE08, ferric citrate, Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Zoledronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S03AA06, gentamicin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Gentamicin is combined with Zoledronic acid.]
[A06AD03, magnesium peroxide, The serum concentration of Zoledronic acid can be decreased when it is combined with Magnesium peroxide.]
[M02AA25, aceclofenac, The risk or severity of gastrointestinal bleeding can be increased when Aceclofenac is combined with Zoledronic acid.]
[M01AB11, acemetacin, The risk or severity of gastrointestinal bleeding can be increased when Acemetacin is combined with Zoledronic acid.]
[J05AF13, tenofovir alafenamide, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tenofovir alafenamide is combined with Zoledronic acid.]
[M01AE16, alminoprofen, The risk or severity of gastrointestinal bleeding can be increased when Alminoprofen is combined with Zoledronic acid.]
[A02AB06, aloglutamol, The serum concentration of Zoledronic acid can be decreased when it is combined with Aloglutamol.]
[A02AD05, aluminum magnesium silicate, The serum concentration of Zoledronic acid can be decreased when it is combined with Almasilate.]
[A02AB03, aluminum phosphate, The serum concentration of Zoledronic acid can be decreased when it is combined with Aluminium phosphate.]
[C03CA02, bumetanide, The risk or severity of hypocalcemia can be increased when Bumetanide is combined with Zoledronic acid.]
[A07EC04, balsalazide, The risk or severity of gastrointestinal bleeding can be increased when Balsalazide is combined with Zoledronic acid.]
[A12AA04, calcium carbonate, The serum concentration of Zoledronic acid can be decreased when it is combined with Calcium carbonate.]
[G04BA03, calcium chloride, The serum concentration of Zoledronic acid can be decreased when it is combined with Calcium chloride.]
[D11AX03, calcium gluconate, The serum concentration of Zoledronic acid can be decreased when it is combined with Calcium gluconate.]
[A12AA01, calcium phosphate, The serum concentration of Zoledronic acid can be decreased when it is combined with Calcium Phosphate.]
[P01AX10, fumagillin, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Fumagillin is combined with Zoledronic acid.]
[A02BX12, bismuth subnitrate, The serum concentration of Zoledronic acid can be decreased when it is combined with Bismuth subnitrate.]
[J01DC10, cefprozil, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefprozil is combined with Zoledronic acid.]
[M01AB07, bumadizone, The risk or severity of gastrointestinal bleeding can be increased when Bumadizone is combined with Zoledronic acid.]
[A06AC08, calcium polycarbophil, The serum concentration of Zoledronic acid can be decreased when it is combined with Calcium polycarbophil.]
[J01DE01, cefepime, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefepime is combined with Zoledronic acid.]
[J01DD10, cefetamet, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefetamet is combined with Zoledronic acid.]
[J01DD09, cefodizime, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefodizime is combined with Zoledronic acid.]
[J01DC11, ceforanide, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceforanide is combined with Zoledronic acid.]
[J01DD13, cefpodoxime, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefpodoxime is combined with Zoledronic acid.]
[J01DD14, ceftibuten, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftibuten is combined with Zoledronic acid.]
[J01GB14, plazomicin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Plazomicin is combined with Zoledronic acid.]
[M01AC05, lornoxicam, The risk or severity of gastrointestinal bleeding can be increased when Lornoxicam is combined with Zoledronic acid.]
[N07XX15, inotersen, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Inotersen is combined with Zoledronic acid.]
[V03AE07, calcium acetate, The serum concentration of Zoledronic acid can be decreased when it is combined with Calcium acetate.]
[J01DC04, cefaclor, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefaclor is combined with Zoledronic acid.]
[J01DB05, cefadroxil, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefadroxil is combined with Zoledronic acid.]
[J01DC03, cefamandole, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefamandole is combined with Zoledronic acid.]
[J01DB07, cefatrizine, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefatrizine is combined with Zoledronic acid.]
[J01DB04, cefazolin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefazolin is combined with Zoledronic acid.]
[J01DC09, cefmetazole, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefmetazole is combined with Zoledronic acid.]
[J01DC06, cefonicid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefonicid is combined with Zoledronic acid.]
[J01DD12, cefoperazone, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefoperazone is combined with Zoledronic acid.]
[J01DD01, cefotaxime, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefotaxime is combined with Zoledronic acid.]
[J01DC05, cefotetan, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefotetan is combined with Zoledronic acid.]
[J01DC07, cefotiam, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefotiam is combined with Zoledronic acid.]
[J01DC01, cefoxitin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefoxitin is combined with Zoledronic acid.]
[J01DD03, cefsulodin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefsulodin is combined with Zoledronic acid.]
[J01DD02, ceftazidime, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftazidime is combined with Zoledronic acid.]
[J01DD07, ceftizoxime, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftizoxime is combined with Zoledronic acid.]
[J01DD04, ceftriaxone, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftriaxone is combined with Zoledronic acid.]
[S01AA27, cefuroxime, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefuroxime is combined with Zoledronic acid.]
[S01LA06, brolucizumab, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Brolucizumab is combined with Zoledronic acid.]
[J01DB01, cephalexin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cephalexin is combined with Zoledronic acid.]
[J01DB02, cephaloridine, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefaloridine is combined with Zoledronic acid.]
[J01DB03, cephalothin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefalotin is combined with Zoledronic acid.]
[J01DB08, cephapirin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefapirin is combined with Zoledronic acid.]
[J01DB09, cephradine, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefradine is combined with Zoledronic acid.]
[A16AX16, givosiran, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Givosiran is combined with Zoledronic acid.]
[M01AH02, rofecoxib, The risk or severity of gastrointestinal bleeding can be increased when Rofecoxib is combined with Zoledronic acid.]
[M01AC04, droxicam, The risk or severity of gastrointestinal bleeding can be increased when Droxicam is combined with Zoledronic acid.]
[M02AA27, dexketoprofen, The risk or severity of gastrointestinal bleeding can be increased when Dexketoprofen is combined with Zoledronic acid.]
[N02BA07, ethenzamide, The risk or severity of gastrointestinal bleeding can be increased when Ethenzamide is combined with Zoledronic acid.]
[M01AB08, etodolac, The risk or severity of gastrointestinal bleeding can be increased when Etodolac is combined with Zoledronic acid.]
[M02AA06, etofenamate, The risk or severity of gastrointestinal bleeding can be increased when Etofenamate is combined with Zoledronic acid.]
[M01AE05, fenbufen, The risk or severity of gastrointestinal bleeding can be increased when Fenbufen is combined with Zoledronic acid.]
[V08CA07, ferric ammonium citrate, Ferric ammonium citrate can cause a decrease in the absorption of Zoledronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V03AB31, prussian blue insoluble, Prussian blue can cause a decrease in the absorption of Zoledronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AB02, iron sucrose, Iron sucrose can cause a decrease in the absorption of Zoledronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA05, ferrous chloride, Ferrous chloride can cause a decrease in the absorption of Zoledronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA02, ferrous fumarate, Ferrous fumarate can cause a decrease in the absorption of Zoledronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA03, ferrous gluconate, Ferrous gluconate can cause a decrease in the absorption of Zoledronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA06, ferrous succinate, Ferrous succinate can cause a decrease in the absorption of Zoledronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA07, ferrous sulfate, Ferrous sulfate anhydrous can cause a decrease in the absorption of Zoledronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01LA08, bevacizumab, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Zoledronic acid.]
[B03AB10, ferric maltol, Ferric maltol can cause a decrease in the absorption of Zoledronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01XA01, cisplatin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cisplatin is combined with Zoledronic acid.]
[M01AG01, mefenamic acid, The risk or severity of gastrointestinal bleeding can be increased when Mefenamic acid is combined with Zoledronic acid.]
[A12AA02, calcium glubionate, The serum concentration of Zoledronic acid can be decreased when it is combined with Calcium glubionate anhydrous.]
[J01GB12, arbekacin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Arbekacin is combined with Zoledronic acid.]
[M01AX13, proquazone, The risk or severity of gastrointestinal bleeding can be increased when Proquazone is combined with Zoledronic acid.]
[J01XB01, colistin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Colistin is combined with Zoledronic acid.]
[J01DE02, cefpirome, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefpirome is combined with Zoledronic acid.]
[A02AD04, hydrotalcite, The serum concentration of Zoledronic acid can be decreased when it is combined with Hydrotalcite.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of gastrointestinal bleeding can be increased when Imidazole salicylate is combined with Zoledronic acid.]
[B01AC10, indobufen, The risk or severity of gastrointestinal bleeding can be increased when Indobufen is combined with Zoledronic acid.]
[M01AH03, valdecoxib, The risk or severity of gastrointestinal bleeding can be increased when Valdecoxib is combined with Zoledronic acid.]
[M01AH04, parecoxib, The risk or severity of gastrointestinal bleeding can be increased when Parecoxib is combined with Zoledronic acid.]
[S01AD03, acyclovir, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Acyclovir is combined with Zoledronic acid.]
[M01AA06, kebuzone, The risk or severity of gastrointestinal bleeding can be increased when Kebuzone is combined with Zoledronic acid.]
[M01AB09, lonazolac, The risk or severity of gastrointestinal bleeding can be increased when Lonazolac is combined with Zoledronic acid.]
[M02AA31, loxoprofen, The risk or severity of gastrointestinal bleeding can be increased when Loxoprofen is combined with Zoledronic acid.]
[J01DC08, loracarbef, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Loracarbef is combined with Zoledronic acid.]
[A02AD02, magaldrate, The serum concentration of Zoledronic acid can be decreased when it is combined with Magaldrate.]
[A06AD01, magnesium carbonate, The serum concentration of Zoledronic acid can be decreased when it is combined with Magnesium carbonate.]
[J05AF07, tenofovir disoproxil, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tenofovir disoproxil is combined with Zoledronic acid.]
[S01XA18, cyclosporine, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Zoledronic acid.]
[M02AA02, mofebutazone, The risk or severity of gastrointestinal bleeding can be increased when Mofebutazone is combined with Zoledronic acid.]
[M01AX22, morniflumate, The risk or severity of gastrointestinal bleeding can be increased when Morniflumate is combined with Zoledronic acid.]
[M01AH05, etoricoxib, The risk or severity of gastrointestinal bleeding can be increased when Etoricoxib is combined with Zoledronic acid.]
[M01AX01, nabumetone, The risk or severity of gastrointestinal bleeding can be increased when Nabumetone is combined with Zoledronic acid.]
[A07EC03, olsalazine, The risk or severity of gastrointestinal bleeding can be increased when Olsalazine is combined with Zoledronic acid.]
[M01AE12, oxaprozin, The risk or severity of gastrointestinal bleeding can be increased when Oxaprozin is combined with Zoledronic acid.]
[M05BA02, clodronic acid, The risk or severity of adverse effects can be increased when Zoledronic acid is combined with Clodronic acid.]
[S01BC03, diclofenac, The risk or severity of gastrointestinal bleeding can be increased when Diclofenac is combined with Zoledronic acid.]
[J05AD01, foscarnet, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Foscarnet is combined with Zoledronic acid.]
[C03CA03, piretanide, The risk or severity of hypocalcemia can be increased when Piretanide is combined with Zoledronic acid.]
[N02BA11, diflunisal, The risk or severity of gastrointestinal bleeding can be increased when Diflunisal is combined with Zoledronic acid.]
[L04AX04, lenalidomide, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Lenalidomide is combined with Zoledronic acid.]
[J05AE08, atazanavir, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Atazanavir is combined with Zoledronic acid.]
[N02BB04, propyphenazone, The risk or severity of gastrointestinal bleeding can be increased when Propyphenazone is combined with Zoledronic acid.]
[M01AB14, proglumetacin, The risk or severity of gastrointestinal bleeding can be increased when Proglumetacin is combined with Zoledronic acid.]
[L01EX01, sunitinib, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Sunitinib is combined with Zoledronic acid.]
[S01BC05, ketorolac, The risk or severity of gastrointestinal bleeding can be increased when Ketorolac is combined with Zoledronic acid.]
[N02BA06, salsalate, The risk or severity of gastrointestinal bleeding can be increased when Salsalate is combined with Zoledronic acid.]
[H05BA01, salmon calcitonin, The risk or severity of hypocalcemia can be increased when Salmon calcitonin is combined with Zoledronic acid.]
[B05XA02, sodium bicarbonate, The serum concentration of Zoledronic acid can be decreased when it is combined with Sodium bicarbonate.]
[M01AC02, tenoxicam, The risk or severity of gastrointestinal bleeding can be increased when Tenoxicam is combined with Zoledronic acid.]
[M01AG02, tolfenamic acid, The risk or severity of gastrointestinal bleeding can be increased when Tolfenamic acid is combined with Zoledronic acid.]
[C03CA04, torsemide, The risk or severity of hypocalcemia can be increased when Torasemide is combined with Zoledronic acid.]
[M01AB04, zomepirac, The risk or severity of gastrointestinal bleeding can be increased when Zomepirac is combined with Zoledronic acid.]
[L01XA02, carboplatin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Carboplatin is combined with Zoledronic acid.]
[M01AC06, meloxicam, The risk or severity of gastrointestinal bleeding can be increased when Meloxicam is combined with Zoledronic acid.]
[L04AD02, tacrolimus, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tacrolimus is combined with Zoledronic acid.]
[M01AE04, fenoprofen, The risk or severity of gastrointestinal bleeding can be increased when Fenoprofen is combined with Zoledronic acid.]
[N02BG04, floctafenine, The risk or severity of gastrointestinal bleeding can be increased when Floctafenine is combined with Zoledronic acid.]
[S01BC04, flurbiprofen, The risk or severity of gastrointestinal bleeding can be increased when Flurbiprofen is combined with Zoledronic acid.]
[S01AA07, framycetin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Framycetin is combined with Zoledronic acid.]
[C03CA01, furosemide, The risk or severity of hypocalcemia can be increased when Furosemide is combined with Zoledronic acid.]
[M05BA04, alendronic acid, The risk or severity of adverse effects can be increased when Zoledronic acid is combined with Alendronic acid.]
[A12AA13, calcium citrate, The serum concentration of Zoledronic acid can be decreased when it is combined with Calcium citrate.]
[A12AA10, calcium gluceptate, The serum concentration of Zoledronic acid can be decreased when it is combined with Calcium glucoheptonate.]
[A12AA05, calcium lactate, The serum concentration of Zoledronic acid can be decreased when it is combined with Calcium lactate.]
[A12AA30, calcium levulinate, The serum concentration of Zoledronic acid can be decreased when it is combined with Calcium levulinate.]
[A07EC02, mesalamine, The risk or severity of gastrointestinal bleeding can be increased when Mesalazine is combined with Zoledronic acid.]
[M02AA26, nimesulide, The risk or severity of gastrointestinal bleeding can be increased when Nimesulide is combined with Zoledronic acid.]
[C03AA03, hydrochlorothiazide, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Hydrochlorothiazide is combined with Zoledronic acid.]
[M05BA07, risedronic acid, The risk or severity of adverse effects can be increased when Zoledronic acid is combined with Risedronic acid.]
[R02AX02, ibuprofen, The risk or severity of gastrointestinal bleeding can be increased when Ibuprofen is combined with Zoledronic acid.]
[S01BC01, indomethacin, The risk or severity of gastrointestinal bleeding can be increased when Indomethacin is combined with Zoledronic acid.]
[S01LA04, ranibizumab, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Ranibizumab is combined with Zoledronic acid.]
[S01AA24, kanamycin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Kanamycin is combined with Zoledronic acid.]
[A02AB01, aluminum hydroxide, The serum concentration of Zoledronic acid can be decreased when it is combined with Aluminum hydroxide.]
[M02AA10, ketoprofen, The risk or severity of gastrointestinal bleeding can be increased when Ketoprofen is combined with Zoledronic acid.]
[V03AC03, deferasirox, The risk or severity of gastrointestinal bleeding and gastrointestinal ulceration can be increased when Zoledronic acid is combined with Deferasirox.]
[M01AE11, tiaprofenic acid, The risk or severity of gastrointestinal bleeding can be increased when Tiaprofenic acid is combined with Zoledronic acid.]
[C03CC01, ethacrynic acid, The risk or severity of hypocalcemia can be increased when Etacrynic acid is combined with Zoledronic acid.]
[S01AA21, amikacin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Amikacin is combined with Zoledronic acid.]
[A12AA11, calcium pangamate, The serum concentration of Zoledronic acid can be decreased when it is combined with Calcium pangamate.]
[G04BX01, magnesium hydroxide, The serum concentration of Zoledronic acid can be decreased when it is combined with Magnesium hydroxide.]
[A12CC10, magnesium oxide, The serum concentration of Zoledronic acid can be decreased when it is combined with Magnesium oxide.]
[V04CX04, mannitol, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Mannitol is combined with Zoledronic acid.]
[M02AA18, meclofenamic acid, The risk or severity of gastrointestinal bleeding can be increased when Meclofenamic acid is combined with Zoledronic acid.]
[L04AX03, methotrexate, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Methotrexate is combined with Zoledronic acid.]
[N02BB03, aminopyrine, The risk or severity of gastrointestinal bleeding can be increased when Aminophenazone is combined with Zoledronic acid.]
[J01DD06, moxalactam, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Latamoxef is combined with Zoledronic acid.]
[L01EX03, pazopanib, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Pazopanib is combined with Zoledronic acid.]
[M02AA12, naproxen, The risk or severity of gastrointestinal bleeding can be increased when Naproxen is combined with Zoledronic acid.]
[S03AA01, neomycin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Neomycin is combined with Zoledronic acid.]
[J02AA01, amphotericin B, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Amphotericin B is combined with Zoledronic acid.]
[S01AA23, netilmicin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Netilmicin is combined with Zoledronic acid.]
[J05AB11, valacyclovir, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Valaciclovir is combined with Zoledronic acid.]
[M02AA17, niflumic acid, The risk or severity of gastrointestinal bleeding can be increased when Niflumic acid is combined with Zoledronic acid.]
[C02DD01, nitroprusside, Nitroprusside can cause a decrease in the absorption of Zoledronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V08CB01, ferumoxsil, Ferumoxsil can cause a decrease in the absorption of Zoledronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01BC02, oxyphenbutazone, The risk or severity of gastrointestinal bleeding can be increased when Oxyphenbutazone is combined with Zoledronic acid.]
[J04AB30, capreomycin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Capreomycin is combined with Zoledronic acid.]
[A07AA06, paromomycin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Paromomycin is combined with Zoledronic acid.]
[G04BX06, phenazopyridine, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Phenazopyridine is combined with Zoledronic acid.]
[M02AA01, phenylbutazone, The risk or severity of gastrointestinal bleeding can be increased when Phenylbutazone is combined with Zoledronic acid.]
[J05AB12, cidofovir, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cidofovir is combined with Zoledronic acid.]
[S01BC06, piroxicam, The risk or severity of gastrointestinal bleeding can be increased when Piroxicam is combined with Zoledronic acid.]
[J01DD16, cefditoren, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefditoren is combined with Zoledronic acid.]
[N02BA05, salicylamide, The risk or severity of gastrointestinal bleeding can be increased when Salicylamide is combined with Zoledronic acid.]
[A07EC01, sulfasalazine, The risk or severity of gastrointestinal bleeding can be increased when Sulfasalazine is combined with Zoledronic acid.]
[S01BC08, salicylic acid, The risk or severity of gastrointestinal bleeding can be increased when Salicylic acid is combined with Zoledronic acid.]
[J01GB08, sisomicin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Sisomicin is combined with Zoledronic acid.]
[S02DA03, antipyrine, The risk or severity of gastrointestinal bleeding can be increased when Antipyrine is combined with Zoledronic acid.]
[J01GA01, streptomycin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Streptomycin is combined with Zoledronic acid.]
[M01AB02, sulindac, The risk or severity of gastrointestinal bleeding can be increased when Sulindac is combined with Zoledronic acid.]
[M01AX04, apazone, The risk or severity of gastrointestinal bleeding can be increased when Azapropazone is combined with Zoledronic acid.]
[J01DI02, ceftaroline fosamil, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftaroline fosamil is combined with Zoledronic acid.]
[L04AX02, thalidomide, The risk or severity of jaw osteonecrosis can be increased when Thalidomide is combined with Zoledronic acid.]
[B03AB03, sodium ironedetate, Sodium feredetate can cause a decrease in the absorption of Zoledronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01AA12, tobramycin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tobramycin is combined with Zoledronic acid.]
[M02AA21, tolmetin, The risk or severity of gastrointestinal bleeding can be increased when Tolmetin is combined with Zoledronic acid.]
[C03DB02, triamterene, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Triamterene is combined with Zoledronic acid.]
[S01AA28, vancomycin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Vancomycin is combined with Zoledronic acid.]
[M05BA03, pamidronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Pamidronic acid is combined with Zoledronic acid.]
[M05BA05, tiludronic acid, The risk or severity of adverse effects can be increased when Zoledronic acid is combined with Tiludronic acid.]
[M05BA06, ibandronic acid, The risk or severity of adverse effects can be increased when Zoledronic acid is combined with Ibandronate.]
[N02BA01, aspirin, The risk or severity of gastrointestinal bleeding can be increased when Acetylsalicylic acid is combined with Zoledronic acid.]
[S01LA05, aflibercept, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Aflibercept is combined with Zoledronic acid.]
[R02AB04, bacitracin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Bacitracin is combined with Zoledronic acid.]
[A02AA05, magnesium silicate, The serum concentration of Zoledronic acid can be decreased when it is combined with Magnesium silicate.]
[A02AC02, calcium silicate, The serum concentration of Zoledronic acid can be decreased when it is combined with Calcium silicate.]
[L04AX06, pomalidomide, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Pomalidomide is combined with Zoledronic acid.]
[N02BA10, benorilate, The risk or severity of gastrointestinal bleeding can be increased when Benorilate is combined with Zoledronic acid.]
[M01AH01, celecoxib, The risk or severity of gastrointestinal bleeding can be increased when Celecoxib is combined with Zoledronic acid.]
[R02AX03, benzydamine, The risk or severity of gastrointestinal bleeding can be increased when Benzydamine is combined with Zoledronic acid.]
[H05AA03, parathyroid hormone, The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Zoledronic acid.]
[B03AB04, ferric hydroxide, Ferric hydroxide can cause a decrease in the absorption of Zoledronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V03AE05, sucroferric oxyhydroxide, Iron sucrose can cause a decrease in the absorption of Zoledronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01AA15, dihydrostreptomycin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Dihydrostreptomycin is combined with Zoledronic acid.]
[V03AE08, ferric citrate, Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Zoledronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S03AA06, gentamicin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Gentamicin is combined with Zoledronic acid.]
[J05AF08, adefovir dipivoxil, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Adefovir dipivoxil is combined with Zoledronic acid.]
[A06AD03, magnesium peroxide, The serum concentration of Zoledronic acid can be decreased when it is combined with Magnesium peroxide.]
[M02AA25, aceclofenac, The risk or severity of gastrointestinal bleeding can be increased when Aceclofenac is combined with Zoledronic acid.]
[M01AB11, acemetacin, The risk or severity of gastrointestinal bleeding can be increased when Acemetacin is combined with Zoledronic acid.]
[J05AF13, tenofovir alafenamide, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tenofovir alafenamide is combined with Zoledronic acid.]
[M01AE16, alminoprofen, The risk or severity of gastrointestinal bleeding can be increased when Alminoprofen is combined with Zoledronic acid.]
[A02AB06, aloglutamol, The serum concentration of Zoledronic acid can be decreased when it is combined with Aloglutamol.]
[A02AD05, aluminum magnesium silicate, The serum concentration of Zoledronic acid can be decreased when it is combined with Almasilate.]
[A02AB03, aluminum phosphate, The serum concentration of Zoledronic acid can be decreased when it is combined with Aluminium phosphate.]
[C03CA02, bumetanide, The risk or severity of hypocalcemia can be increased when Bumetanide is combined with Zoledronic acid.]
[A07EC04, balsalazide, The risk or severity of gastrointestinal bleeding can be increased when Balsalazide is combined with Zoledronic acid.]
[A12AA04, calcium carbonate, The serum concentration of Zoledronic acid can be decreased when it is combined with Calcium carbonate.]
[G04BA03, calcium chloride, The serum concentration of Zoledronic acid can be decreased when it is combined with Calcium chloride.]
[D11AX03, calcium gluconate, The serum concentration of Zoledronic acid can be decreased when it is combined with Calcium gluconate.]
[A12AA01, calcium phosphate, The serum concentration of Zoledronic acid can be decreased when it is combined with Calcium Phosphate.]
[P01AX10, fumagillin, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Fumagillin is combined with Zoledronic acid.]
[A02BX12, bismuth subnitrate, The serum concentration of Zoledronic acid can be decreased when it is combined with Bismuth subnitrate.]
[J01DC10, cefprozil, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefprozil is combined with Zoledronic acid.]
[M01AB07, bumadizone, The risk or severity of gastrointestinal bleeding can be increased when Bumadizone is combined with Zoledronic acid.]
[A06AC08, calcium polycarbophil, The serum concentration of Zoledronic acid can be decreased when it is combined with Calcium polycarbophil.]
[J01DE01, cefepime, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefepime is combined with Zoledronic acid.]
[J01DD10, cefetamet, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefetamet is combined with Zoledronic acid.]
[J01DD09, cefodizime, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefodizime is combined with Zoledronic acid.]
[J01DC11, ceforanide, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceforanide is combined with Zoledronic acid.]
[J01DD13, cefpodoxime, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefpodoxime is combined with Zoledronic acid.]
[J01DD14, ceftibuten, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftibuten is combined with Zoledronic acid.]
[J01GB14, plazomicin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Plazomicin is combined with Zoledronic acid.]
[M01AC05, lornoxicam, The risk or severity of gastrointestinal bleeding can be increased when Lornoxicam is combined with Zoledronic acid.]
[N07XX15, inotersen, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Inotersen is combined with Zoledronic acid.]
[V03AE07, calcium acetate, The serum concentration of Zoledronic acid can be decreased when it is combined with Calcium acetate.]
[J01DC04, cefaclor, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefaclor is combined with Zoledronic acid.]
[J01DB05, cefadroxil, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefadroxil is combined with Zoledronic acid.]
[J01DC03, cefamandole, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefamandole is combined with Zoledronic acid.]
[J01DB07, cefatrizine, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefatrizine is combined with Zoledronic acid.]
[J01DB04, cefazolin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefazolin is combined with Zoledronic acid.]
[J01DC09, cefmetazole, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefmetazole is combined with Zoledronic acid.]
[J01DC06, cefonicid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefonicid is combined with Zoledronic acid.]
[J01DD12, cefoperazone, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefoperazone is combined with Zoledronic acid.]
[J01DD01, cefotaxime, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefotaxime is combined with Zoledronic acid.]
[J01DC05, cefotetan, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefotetan is combined with Zoledronic acid.]
[J01DC07, cefotiam, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefotiam is combined with Zoledronic acid.]
[J01DC01, cefoxitin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefoxitin is combined with Zoledronic acid.]
[J01DD03, cefsulodin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefsulodin is combined with Zoledronic acid.]
[J01DD02, ceftazidime, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftazidime is combined with Zoledronic acid.]
[J01DD07, ceftizoxime, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftizoxime is combined with Zoledronic acid.]
[J01DD04, ceftriaxone, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftriaxone is combined with Zoledronic acid.]
[S01AA27, cefuroxime, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefuroxime is combined with Zoledronic acid.]
[S01LA06, brolucizumab, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Brolucizumab is combined with Zoledronic acid.]
[J01DB01, cephalexin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cephalexin is combined with Zoledronic acid.]
[J01DB02, cephaloridine, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefaloridine is combined with Zoledronic acid.]
[J01DB03, cephalothin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefalotin is combined with Zoledronic acid.]
[J01DB08, cephapirin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefapirin is combined with Zoledronic acid.]
[J01DB09, cephradine, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefradine is combined with Zoledronic acid.]
[A16AX16, givosiran, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Givosiran is combined with Zoledronic acid.]
[M01AH02, rofecoxib, The risk or severity of gastrointestinal bleeding can be increased when Rofecoxib is combined with Zoledronic acid.]
[M01AC04, droxicam, The risk or severity of gastrointestinal bleeding can be increased when Droxicam is combined with Zoledronic acid.]
[M02AA27, dexketoprofen, The risk or severity of gastrointestinal bleeding can be increased when Dexketoprofen is combined with Zoledronic acid.]
[N02BA07, ethenzamide, The risk or severity of gastrointestinal bleeding can be increased when Ethenzamide is combined with Zoledronic acid.]
[M01AB08, etodolac, The risk or severity of gastrointestinal bleeding can be increased when Etodolac is combined with Zoledronic acid.]
[M02AA06, etofenamate, The risk or severity of gastrointestinal bleeding can be increased when Etofenamate is combined with Zoledronic acid.]
[M01AE05, fenbufen, The risk or severity of gastrointestinal bleeding can be increased when Fenbufen is combined with Zoledronic acid.]
[V08CA07, ferric ammonium citrate, Ferric ammonium citrate can cause a decrease in the absorption of Zoledronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V03AB31, prussian blue insoluble, Prussian blue can cause a decrease in the absorption of Zoledronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AB02, iron sucrose, Iron sucrose can cause a decrease in the absorption of Zoledronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA05, ferrous chloride, Ferrous chloride can cause a decrease in the absorption of Zoledronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA02, ferrous fumarate, Ferrous fumarate can cause a decrease in the absorption of Zoledronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA03, ferrous gluconate, Ferrous gluconate can cause a decrease in the absorption of Zoledronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA06, ferrous succinate, Ferrous succinate can cause a decrease in the absorption of Zoledronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA07, ferrous sulfate, Ferrous sulfate anhydrous can cause a decrease in the absorption of Zoledronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01LA08, bevacizumab, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Zoledronic acid.]
[B03AB10, ferric maltol, Ferric maltol can cause a decrease in the absorption of Zoledronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01XA01, cisplatin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cisplatin is combined with Zoledronic acid.]
[M01AG01, mefenamic acid, The risk or severity of gastrointestinal bleeding can be increased when Mefenamic acid is combined with Zoledronic acid.]
[A12AA02, calcium glubionate, The serum concentration of Zoledronic acid can be decreased when it is combined with Calcium glubionate anhydrous.]
[J01GB12, arbekacin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Arbekacin is combined with Zoledronic acid.]
[M01AX13, proquazone, The risk or severity of gastrointestinal bleeding can be increased when Proquazone is combined with Zoledronic acid.]
[J01XB01, colistin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Colistin is combined with Zoledronic acid.]
[J01DE02, cefpirome, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefpirome is combined with Zoledronic acid.]
[A02AD04, hydrotalcite, The serum concentration of Zoledronic acid can be decreased when it is combined with Hydrotalcite.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of gastrointestinal bleeding can be increased when Imidazole salicylate is combined with Zoledronic acid.]
[B01AC10, indobufen, The risk or severity of gastrointestinal bleeding can be increased when Indobufen is combined with Zoledronic acid.]
[M01AH03, valdecoxib, The risk or severity of gastrointestinal bleeding can be increased when Valdecoxib is combined with Zoledronic acid.]
[M01AH04, parecoxib, The risk or severity of gastrointestinal bleeding can be increased when Parecoxib is combined with Zoledronic acid.]
[S01AD03, acyclovir, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Acyclovir is combined with Zoledronic acid.]
[M01AA06, kebuzone, The risk or severity of gastrointestinal bleeding can be increased when Kebuzone is combined with Zoledronic acid.]
[M01AB09, lonazolac, The risk or severity of gastrointestinal bleeding can be increased when Lonazolac is combined with Zoledronic acid.]
[M02AA31, loxoprofen, The risk or severity of gastrointestinal bleeding can be increased when Loxoprofen is combined with Zoledronic acid.]
[J01DC08, loracarbef, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Loracarbef is combined with Zoledronic acid.]
[A02AD02, magaldrate, The serum concentration of Zoledronic acid can be decreased when it is combined with Magaldrate.]
[A06AD01, magnesium carbonate, The serum concentration of Zoledronic acid can be decreased when it is combined with Magnesium carbonate.]
[J05AF07, tenofovir disoproxil, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tenofovir disoproxil is combined with Zoledronic acid.]
[S01XA18, cyclosporine, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Zoledronic acid.]
[M02AA02, mofebutazone, The risk or severity of gastrointestinal bleeding can be increased when Mofebutazone is combined with Zoledronic acid.]
[M01AX22, morniflumate, The risk or severity of gastrointestinal bleeding can be increased when Morniflumate is combined with Zoledronic acid.]
[M01AH05, etoricoxib, The risk or severity of gastrointestinal bleeding can be increased when Etoricoxib is combined with Zoledronic acid.]
[M01AX01, nabumetone, The risk or severity of gastrointestinal bleeding can be increased when Nabumetone is combined with Zoledronic acid.]
[A07EC03, olsalazine, The risk or severity of gastrointestinal bleeding can be increased when Olsalazine is combined with Zoledronic acid.]
[M01AE12, oxaprozin, The risk or severity of gastrointestinal bleeding can be increased when Oxaprozin is combined with Zoledronic acid.]
[M05BA02, clodronic acid, The risk or severity of adverse effects can be increased when Zoledronic acid is combined with Clodronic acid.]
[S01BC03, diclofenac, The risk or severity of gastrointestinal bleeding can be increased when Diclofenac is combined with Zoledronic acid.]
[J05AD01, foscarnet, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Foscarnet is combined with Zoledronic acid.]
[C03CA03, piretanide, The risk or severity of hypocalcemia can be increased when Piretanide is combined with Zoledronic acid.]
[N02BA11, diflunisal, The risk or severity of gastrointestinal bleeding can be increased when Diflunisal is combined with Zoledronic acid.]
[L04AX04, lenalidomide, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Lenalidomide is combined with Zoledronic acid.]
[J05AE08, atazanavir, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Atazanavir is combined with Zoledronic acid.]
[N02BB04, propyphenazone, The risk or severity of gastrointestinal bleeding can be increased when Propyphenazone is combined with Zoledronic acid.]
[M01AB14, proglumetacin, The risk or severity of gastrointestinal bleeding can be increased when Proglumetacin is combined with Zoledronic acid.]
[L01EX01, sunitinib, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Sunitinib is combined with Zoledronic acid.]
[S01BC05, ketorolac, The risk or severity of gastrointestinal bleeding can be increased when Ketorolac is combined with Zoledronic acid.]
[N02BA06, salsalate, The risk or severity of gastrointestinal bleeding can be increased when Salsalate is combined with Zoledronic acid.]
[H05BA01, salmon calcitonin, The risk or severity of hypocalcemia can be increased when Salmon calcitonin is combined with Zoledronic acid.]
[B05XA02, sodium bicarbonate, The serum concentration of Zoledronic acid can be decreased when it is combined with Sodium bicarbonate.]
[M01AC02, tenoxicam, The risk or severity of gastrointestinal bleeding can be increased when Tenoxicam is combined with Zoledronic acid.]
[M01AG02, tolfenamic acid, The risk or severity of gastrointestinal bleeding can be increased when Tolfenamic acid is combined with Zoledronic acid.]
[C03CA04, torsemide, The risk or severity of hypocalcemia can be increased when Torasemide is combined with Zoledronic acid.]
[M01AB04, zomepirac, The risk or severity of gastrointestinal bleeding can be increased when Zomepirac is combined with Zoledronic acid.]
[L01XA02, carboplatin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Carboplatin is combined with Zoledronic acid.]
[M01AC06, meloxicam, The risk or severity of gastrointestinal bleeding can be increased when Meloxicam is combined with Zoledronic acid.]
[L04AD02, tacrolimus, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tacrolimus is combined with Zoledronic acid.]
[M05BA01, etidronic acid, The risk or severity of adverse effects can be increased when Zoledronic acid is combined with Etidronic acid.]
[M01AE04, fenoprofen, The risk or severity of gastrointestinal bleeding can be increased when Fenoprofen is combined with Zoledronic acid.]
[N02BG04, floctafenine, The risk or severity of gastrointestinal bleeding can be increased when Floctafenine is combined with Zoledronic acid.]
[S01BC04, flurbiprofen, The risk or severity of gastrointestinal bleeding can be increased when Flurbiprofen is combined with Zoledronic acid.]
[S01AA07, framycetin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Framycetin is combined with Zoledronic acid.]
[C03CA01, furosemide, The risk or severity of hypocalcemia can be increased when Furosemide is combined with Zoledronic acid.]
[M05BA04, alendronic acid, The risk or severity of adverse effects can be increased when Zoledronic acid is combined with Alendronic acid.]
[A12AA13, calcium citrate, The serum concentration of Zoledronic acid can be decreased when it is combined with Calcium citrate.]
[A12AA10, calcium gluceptate, The serum concentration of Zoledronic acid can be decreased when it is combined with Calcium glucoheptonate.]
[A12AA05, calcium lactate, The serum concentration of Zoledronic acid can be decreased when it is combined with Calcium lactate.]
[A12AA30, calcium levulinate, The serum concentration of Zoledronic acid can be decreased when it is combined with Calcium levulinate.]
[A07EC02, mesalamine, The risk or severity of gastrointestinal bleeding can be increased when Mesalazine is combined with Zoledronic acid.]
[M02AA26, nimesulide, The risk or severity of gastrointestinal bleeding can be increased when Nimesulide is combined with Zoledronic acid.]
[C03AA03, hydrochlorothiazide, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Hydrochlorothiazide is combined with Zoledronic acid.]
[M05BA07, risedronic acid, The risk or severity of adverse effects can be increased when Zoledronic acid is combined with Risedronic acid.]
[R02AX02, ibuprofen, The risk or severity of gastrointestinal bleeding can be increased when Ibuprofen is combined with Zoledronic acid.]
[S01BC01, indomethacin, The risk or severity of gastrointestinal bleeding can be increased when Indomethacin is combined with Zoledronic acid.]
[S01LA04, ranibizumab, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Ranibizumab is combined with Zoledronic acid.]
[S01AA24, kanamycin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Kanamycin is combined with Zoledronic acid.]
[A02AB01, aluminum hydroxide, The serum concentration of Zoledronic acid can be decreased when it is combined with Aluminum hydroxide.]
[M02AA10, ketoprofen, The risk or severity of gastrointestinal bleeding can be increased when Ketoprofen is combined with Zoledronic acid.]
[V03AC03, deferasirox, The risk or severity of gastrointestinal bleeding and gastrointestinal ulceration can be increased when Zoledronic acid is combined with Deferasirox.]
[M01AE11, tiaprofenic acid, The risk or severity of gastrointestinal bleeding can be increased when Tiaprofenic acid is combined with Zoledronic acid.]
[C03CC01, ethacrynic acid, The risk or severity of hypocalcemia can be increased when Etacrynic acid is combined with Zoledronic acid.]
[S01AA21, amikacin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Amikacin is combined with Zoledronic acid.]
[A12AA11, calcium pangamate, The serum concentration of Zoledronic acid can be decreased when it is combined with Calcium pangamate.]
[G04BX01, magnesium hydroxide, The serum concentration of Zoledronic acid can be decreased when it is combined with Magnesium hydroxide.]
[A12CC10, magnesium oxide, The serum concentration of Zoledronic acid can be decreased when it is combined with Magnesium oxide.]
[V04CX04, mannitol, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Mannitol is combined with Zoledronic acid.]
[M02AA18, meclofenamic acid, The risk or severity of gastrointestinal bleeding can be increased when Meclofenamic acid is combined with Zoledronic acid.]
[L04AX03, methotrexate, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Methotrexate is combined with Zoledronic acid.]
[N02BB03, aminopyrine, The risk or severity of gastrointestinal bleeding can be increased when Aminophenazone is combined with Zoledronic acid.]
[J01DD06, moxalactam, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Latamoxef is combined with Zoledronic acid.]
[L01EX03, pazopanib, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Pazopanib is combined with Zoledronic acid.]
[M02AA12, naproxen, The risk or severity of gastrointestinal bleeding can be increased when Naproxen is combined with Zoledronic acid.]
[S03AA01, neomycin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Neomycin is combined with Zoledronic acid.]
[J02AA01, amphotericin B, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Amphotericin B is combined with Zoledronic acid.]
[S01AA23, netilmicin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Netilmicin is combined with Zoledronic acid.]
[J05AB11, valacyclovir, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Valaciclovir is combined with Zoledronic acid.]
[M02AA17, niflumic acid, The risk or severity of gastrointestinal bleeding can be increased when Niflumic acid is combined with Zoledronic acid.]
[C02DD01, nitroprusside, Nitroprusside can cause a decrease in the absorption of Zoledronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V08CB01, ferumoxsil, Ferumoxsil can cause a decrease in the absorption of Zoledronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01BC02, oxyphenbutazone, The risk or severity of gastrointestinal bleeding can be increased when Oxyphenbutazone is combined with Zoledronic acid.]
[J04AB30, capreomycin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Capreomycin is combined with Zoledronic acid.]
[A07AA06, paromomycin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Paromomycin is combined with Zoledronic acid.]
[G04BX06, phenazopyridine, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Phenazopyridine is combined with Zoledronic acid.]
[M02AA01, phenylbutazone, The risk or severity of gastrointestinal bleeding can be increased when Phenylbutazone is combined with Zoledronic acid.]
[J05AB12, cidofovir, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cidofovir is combined with Zoledronic acid.]
[S01BC06, piroxicam, The risk or severity of gastrointestinal bleeding can be increased when Piroxicam is combined with Zoledronic acid.]
[J01DD16, cefditoren, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefditoren is combined with Zoledronic acid.]
[N02BA05, salicylamide, The risk or severity of gastrointestinal bleeding can be increased when Salicylamide is combined with Zoledronic acid.]
[A07EC01, sulfasalazine, The risk or severity of gastrointestinal bleeding can be increased when Sulfasalazine is combined with Zoledronic acid.]
[S01BC08, salicylic acid, The risk or severity of gastrointestinal bleeding can be increased when Salicylic acid is combined with Zoledronic acid.]
[J01GB08, sisomicin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Sisomicin is combined with Zoledronic acid.]
